| Positive Rankings |
Positive Stoch Cross
Proteostasis Therapeutics rank is 399 |
Debt-to-Equity
Proteostasis Therapeutics rank is 827 |
Price-to-Book
Proteostasis Therapeutics rank is 1064 |
| Negative Rankings |
90 Day Loss
Proteostasis Therapeutics rank is 167 |
Negative Net Margin
Proteostasis Therapeutics rank is 182 |
Down EPS Surprise
Proteostasis Therapeutics missed the consensus earnings estimate when it last reported quarterly earnings. |
10 Day Loss
Proteostasis Therapeutics rank is 321 |
Price-to-Sales
Proteostasis Therapeutics rank is 350 |
Negative ROE
Proteostasis Therapeutics rank is 394 |
Negative ROA
Proteostasis Therapeutics rank is 435 |
